

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): April 5, 2013**

---

**CRYO CELL International, Inc.**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-23386**  
(Commission  
File No.)

**22-3023093**  
(I.R.S. Employer  
Identification No.)

**700 Brooker Creek Boulevard, Oldsmar, Florida**  
(Address of Principal Executive Offices)

**34677**  
(Zip Code)

**Registrant's telephone number, including area code: (813) 749-2100**

**Not Applicable**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 2.02. Results of Operations and Financial Condition.**

On April 5, 2013, Cryo-Cell International, Inc. (the “Registrant”) issued the attached Press Release reporting on financial results for the three months ended February 28, 2013. The press release giving details associated with the Registrant’s earnings is attached as Exhibit 99.1 to this report. The information included in Exhibit 99.1 is considered to be “furnished” under the Securities Exchange Act of 1934.

**Item 9.01. Financial Statements and Exhibits.**

Financial Statements of Businesses Acquired.	Not Applicable.
Pro Forma Financial Information	Not Applicable.
Shell Company Transactions	Not Applicable.
Exhibits.	
Exhibit No.	Description
99.1	Press Release, dated April 5, 2013

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

CRYO CELL International, Inc.

DATE: April 5, 2013

By: /s/ David Portnoy

David Portnoy

Chairman, Co-CEO

For Immediate Release

**Contact:**

David Portnoy  
Chairman and Co-Chief Executive Officer  
Cryo-Cell International, Inc.  
813-749-2100  
[dportnoy@cryo-cell.com](mailto:dportnoy@cryo-cell.com)

**CRYO-CELL REPORTS FIRST QUARTER 2013 RESULTS**

**OLDSMAR, Fla. – April 5, 2013 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL)**(the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced results for the first quarter ended February 28, 2013.

“I am pleased to report Cryo-Cell’s first quarter results, and in particular, cash flow from operations of slightly more than \$500,000, which we believe indicates that the Cryo-Cell turnaround is well underway,” stated David Portnoy, Cryo-Cell’s Chairman and Co-CEO. “Key metrics of performance such as the increase in revenues and the number of specimens processed of 10% and 12%, respectively, during the first quarter of fiscal 2013 as compared to the first quarter of fiscal 2012 are encouraging.”

Mark Portnoy, Cryo-Cell’s Co-CEO, added, “It is gratifying to see the progress the Company has made over the last year although we are still dealing with a variety of legacy issues. With the continued execution of the new sales and marketing initiatives, I expect to see further increases in revenue and earnings.”

**Financial Results**

***Revenue***

Consolidated revenues for the first quarter of fiscal 2013 were approximately \$4.6 million compared to approximately \$4.2 million for the first quarter of fiscal 2012, a 10% increase. The revenues for the first quarter of fiscal 2013 consisted of approximately \$4.3 million in processing and storage fees and approximately \$324,000 in licensee income compared to approximately \$3.8 million in processing and storage fees and approximately \$342,000 in licensee income for the first quarter of fiscal 2012. The increase in processing and storage fees is primarily attributable to an increase in specimens processed of 12% during the first quarter of fiscal 2013 versus the same period in fiscal 2012. Licensee income for the three months ended February 28, 2013 and February 29, 2012 consisted of approximately \$324,000 and \$337,000, respectively, of royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements.

***Net Income***

The Company reported net income for the three months ended February 28, 2013 of approximately \$244,000, or \$0.02 per basic and diluted share, compared to a net loss of approximately (\$1.7 million), or (\$0.15) per basic and diluted share for the three months ended February 29, 2012. The increase in net income for the three months ended February 28, 2013 principally resulted from a 10% increase in revenues and a 15% decrease in selling, general and administrative expenses, offset in part by a 25% increase in cost of sales. During the three months ended February 29, 2012, the cancellation of the Bio-Stor Revenue Sharing Agreement resulted in a pre-tax charge for extinguishment of debt in the amount of approximately \$1,200,000.

---

**Cash and Cash Equivalent Position**

At February 28, 2013, the Company had cash and cash equivalents of approximately \$2.9 million. The Company's cash increased by approximately \$180,000 during the first three months of fiscal 2013, primarily as a result of approximately \$500,000 provided by operations, partially offset by approximately \$250,000 used for the stock repurchase plan pursuant to which the Company repurchased 107,128 shares of the Company's common stock during the three months ended February 28, 2013. As of February 28, 2013, the Company had no long-term indebtedness.

**About Cryo-Cell International, Inc.**

Cryo-Cell International, Inc. was founded in 1989 and was the world's first private cord blood bank to separate and store stem cells in 1992. Today, Cryo-Cell has over 240,000 clients worldwide from 87 countries. Cryo-Cell's mission is to provide its clients with the premier stem cell cryopreservation service and to support the advancement of regenerative medicine.

Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility, is ISO 9001:2008 certified and accredited by the AABB. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit [www.cryo-cell.com](http://www.cryo-cell.com).

**Forward-Looking Statement**

Statements wherein the terms "believes", "intends", "projects", "anticipates", "expects", and similar expressions as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the success of the Company's global expansion initiatives and product diversification, the Company's actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company's future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company's business, the Company's ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company's menstrual stem cell technology license agreements and umbilical cord blood license agreements and their ability to provide the Company with royalty fees, the ability of the reproductive tissue storage to generate new revenues for the Company and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.